233 related articles for article (PubMed ID: 18651401)
1. Impact of nebivolol on levels of serum nitric oxide, plasma von Willebrand factor and exercise stress testing parameters in hypertensive and ischemic heart disease patients.
Kobusiak-Prokopowicz M; Jołda-Mydłowska B; Zubkiewicz A; Szymczak M; Mysiak A; Skalik R
Cardiol J; 2008; 15(2):162-8. PubMed ID: 18651401
[TBL] [Abstract][Full Text] [Related]
2. Integrated effects of the vasodilating beta-blocker nebivolol on exercise performance, energy metabolism, cardiovascular and neurohormonal parameters in physically active patients with arterial hypertension.
Predel HG; Mainka W; Schillings W; Knigge H; Montiel J; Fallois J; Agrawal R; Schramm T; Graf C; Giannetti BM; Bjarnason-Wehrens B; Prinz U; Rost RE
J Hum Hypertens; 2001 Oct; 15(10):715-21. PubMed ID: 11607802
[TBL] [Abstract][Full Text] [Related]
3. Nebivolol therapy improves endothelial function and increases exercise tolerance in patients with cardiac syndrome X.
Sen N; Tavil Y; Erdamar H; Yazici HU; Cakir E; Akgül EO; Bilgi C; Erbil MK; Poyraz F; Okyay K; Turfan M; Cemri M
Anadolu Kardiyol Derg; 2009 Oct; 9(5):371-9. PubMed ID: 19819787
[TBL] [Abstract][Full Text] [Related]
4. Effect of nebivolol on blood oxygen transport indices and endothelial dysfunction in patients with arterial hypertension.
Pronko TP; Zinchuk VV
Clin Physiol Funct Imaging; 2009 May; 29(3):170-6. PubMed ID: 19170724
[TBL] [Abstract][Full Text] [Related]
5. Effect of nebivolol and metoprolol treatments on serum asymmetric dimethylarginine levels in hypertensive patients with type 2 diabetes mellitus.
Oğuz A; Uzunlulu M; Yorulmaz E; Yalçin Y; Hekim N; Fici F
Anadolu Kardiyol Derg; 2007 Dec; 7(4):383-7. PubMed ID: 18065333
[TBL] [Abstract][Full Text] [Related]
6. [Functional and biochemical characteristics of the vasodilator effects of nebivolol in patients with arterial hypertension].
Gel'tser BI; Kotel'niko v VN; Savchenko SV
Ter Arkh; 2002; 74(12):34-7. PubMed ID: 12577837
[TBL] [Abstract][Full Text] [Related]
7. [Nebivolol, a beta blocker of the 3rd generation: modern therapy of arterial hypertension. Results of a multicenter observation study].
von Fallois J; Faulhaber HD
Praxis (Bern 1994); 2001 Mar; 90(11):435-41. PubMed ID: 11293936
[TBL] [Abstract][Full Text] [Related]
8. Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide.
Gupta S; Wright HM
Cardiovasc Ther; 2008; 26(3):189-202. PubMed ID: 18786089
[TBL] [Abstract][Full Text] [Related]
9. [Nebivolol, a third generation beta blocker: the modern treatment of hypertension. Results of a multicentric observational study].
von Fallois J; Faülhaber HD
Fortschr Med Orig; 2000 Jul; 118 Suppl 2():77-82. PubMed ID: 15700490
[TBL] [Abstract][Full Text] [Related]
10. Nitric oxide mechanisms of nebivolol.
Maffei A; Lembo G
Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):317-27. PubMed ID: 19443516
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacological modulation of NO synthesis in patients with arterial hypertension and endothelial dysfunction].
Buval'tsev VI; Spasskaia MB; Nebieridze DV; Metel'skaia VA; Guseva OI
Klin Med (Mosk); 2003; 81(7):51-5. PubMed ID: 12934313
[TBL] [Abstract][Full Text] [Related]
12. Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients.
Kaiser T; Heise T; Nosek L; Eckers U; Sawicki PT
J Hypertens; 2006 Jul; 24(7):1397-403. PubMed ID: 16794490
[TBL] [Abstract][Full Text] [Related]
13. [Platelet activation and endothelial factors in standard exercise test before and after menopause].
Krzysiek J; Milewicz T; Dybkowski R; Janczak-Saif A; Dembińska-Kieć A; Anna AZ; Guevara I; Sztefko K; Radowicki S; Dubiel JS; Klimek R
Przegl Lek; 2001; 58(5):419-25. PubMed ID: 11603175
[TBL] [Abstract][Full Text] [Related]
14. Influence of nebivolol on endothelial dysfunction in salt-sensitive hypertension.
Ugrekhelidze J; Simonia G; Andronikashvili I; Kutateladze M
Georgian Med News; 2006 Apr; (133):56-8. PubMed ID: 16705229
[TBL] [Abstract][Full Text] [Related]
15. Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart.
Rozec B; Erfanian M; Laurent K; Trochu JN; Gauthier C
J Am Coll Cardiol; 2009 Apr; 53(17):1532-8. PubMed ID: 19389564
[TBL] [Abstract][Full Text] [Related]
16. Long-term nebivolol administration reduces renal fibrosis and prevents endothelial dysfunction in rats with hypertension induced by renal mass reduction.
Pires MJ; Rodríguez-Peña AB; Arévalo M; Cenador B; Evangelista S; Esteller A; Sánchez-Rodríguez A; Colaço A; López-Novoa JM
J Hypertens; 2007 Dec; 25(12):2486-96. PubMed ID: 17984671
[TBL] [Abstract][Full Text] [Related]
17. Beta-blockers in the management of hypertension: focus on nebivolol.
Wojciechowski D; Papademetriou V
Expert Rev Cardiovasc Ther; 2008 Apr; 6(4):471-9. PubMed ID: 18402537
[TBL] [Abstract][Full Text] [Related]
18. [Cardiorenal pathology in diabetes mellitus type 1: mechanisms of development and medical correction].
Shestakov MV; Iarek-Martynova IR; Kukharenko SS; Aleksandrov AA; Dedov II
Ter Arkh; 2005; 77(6):40-5. PubMed ID: 16078599
[TBL] [Abstract][Full Text] [Related]
19. Effects of the systemic beta-adrenoceptor antagonist nebivolol on ocular hemodynamics in glaucoma patients.
Zeitz O; Galambos P; Matthiesen N; Wagenfeld L; Schillinger W; Wiermann A; Richard G; Klemm M
Med Sci Monit; 2008 May; 14(5):CR268-275. PubMed ID: 18443551
[TBL] [Abstract][Full Text] [Related]
20. Beneficial effects of switching from beta-blockers to nebivolol on the erectile function of hypertensive patients.
Doumas M; Tsakiris A; Douma S; Grigorakis A; Papadopoulos A; Hounta A; Tsiodras S; Dimitriou D; Giamarellou H
Asian J Androl; 2006 Mar; 8(2):177-82. PubMed ID: 16491268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
